TC-520

N/A

Report date: 2023/03/05 18:10:26

Base Information

Drug NameTC-520
Drug Alias NameTC-520
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionInterleukin-15 receptors agonistsImmunologic cytotoxicityT lymphocyte replacements
TargetsInterleukin-15 receptors
Therapy Area/IndicationsCarcinoma, Renal Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesTcr2 Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesTcr2 Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsCarcinoma, Renal Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A